Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2019

Date: April 29, 2019
Pages: 504
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: CA2C4AF7B2FEN
Leaflet:

Download PDF Leaflet

Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2019
Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2019

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2019, provides an overview of the Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline landscape.

Heart failure is also known as congestive heart failure (CHF). CHF is a condition in which the heart is no longer able to pump out enough oxygen-rich blood. Symptoms include cough, fatigue, weakness, faintness, loss of appetite, swollen (enlarged) liver or abdomen, swollen feet and ankles and weight gain. There are two types of heart failure including systolic heart failure (left ventricle loses its ability to contract normally) and diastolic heart failure (left ventricle loses its ability to relax normally). The predisposing factors include high blood pressure, diabetes, sleep apnea, alcohol use and irregular heartbeats. Treatment includes surgery, vasodilator, beta blockers and diuretics.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Congestive Heart Failure (Heart Failure) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Congestive Heart Failure (Heart Failure) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 14, 27, 23, 3, 68 and 19 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 19 and 4 molecules, respectively.

Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Congestive Heart Failure (Heart Failure) (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Congestive Heart Failure (Heart Failure) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Congestive Heart Failure (Heart Failure) (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Congestive Heart Failure (Heart Failure) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Congestive Heart Failure (Heart Failure) (Cardiovascular)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Congestive Heart Failure (Heart Failure) (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


NOTE: Out of security concerns Global Markets Direct requires using corporate email address.
Introduction
Congestive Heart Failure (Heart Failure) - Overview
Congestive Heart Failure (Heart Failure) - Therapeutics Development
Congestive Heart Failure (Heart Failure) - Therapeutics Assessment
Congestive Heart Failure (Heart Failure) - Companies Involved in Therapeutics Development
Congestive Heart Failure (Heart Failure) - Drug Profiles
Congestive Heart Failure (Heart Failure) - Dormant Projects
Congestive Heart Failure (Heart Failure) - Discontinued Products
Congestive Heart Failure (Heart Failure) - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Congestive Heart Failure (Heart Failure), H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Number of Products under Development by Universities/Institutes, H1 2019 (Contd..1), H1 2019
Products under Development by Companies, H1 2019
Products under Development by Universities/Institutes, H1 2019
Products under Development by Universities/Institutes, H1 2019 (Contd..1), H1 2019
Number of Products by Stage and Target, H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Congestive Heart Failure (Heart Failure) - Pipeline by Actelion Pharmaceuticals Ltd, H1 2019
Congestive Heart Failure (Heart Failure) - Pipeline by Adrenomed AG, H1 2019
Congestive Heart Failure (Heart Failure) - Pipeline by Amgen Inc, H1 2019
Congestive Heart Failure (Heart Failure) - Pipeline by Araim Pharmaceuticals Inc, H1 2019
Congestive Heart Failure (Heart Failure) - Pipeline by ARCA biopharma Inc, H1 2019
Congestive Heart Failure (Heart Failure) - Pipeline by Arena Pharmaceuticals Inc, H1 2019
Congestive Heart Failure (Heart Failure) - Pipeline by Ascendia Pharmaceuticals LLC, H1 2019
Congestive Heart Failure (Heart Failure) - Pipeline by Astellas Pharma Inc, H1 2019
Congestive Heart Failure (Heart Failure) - Pipeline by AstraZeneca Plc, H1 2019
Congestive Heart Failure (Heart Failure) - Pipeline by Athersys Inc, H1 2019
Congestive Heart Failure (Heart Failure) - Pipeline by Bayer AG, H1 2019
Congestive Heart Failure (Heart Failure) - Pipeline by BEAT BioTherapeutics Corp, H1 2019
Congestive Heart Failure (Heart Failure) - Pipeline by Betagenon AB, H1 2019
Congestive Heart Failure (Heart Failure) - Pipeline by BioCardia Inc, H1 2019
Congestive Heart Failure (Heart Failure) - Pipeline by BlueRock Therapeutics, H1 2019
Congestive Heart Failure (Heart Failure) - Pipeline by Boehringer Ingelheim GmbH, H1 2019
Congestive Heart Failure (Heart Failure) - Pipeline by Bristol-Myers Squibb Co, H1 2019
Congestive Heart Failure (Heart Failure) - Pipeline by C&C BioPharma LLC, H1 2019
Congestive Heart Failure (Heart Failure) - Pipeline by Capricor Therapeutics Inc, H1 2019
Congestive Heart Failure (Heart Failure) - Pipeline by Cardiol Therapeutics Inc, H1 2019
Congestive Heart Failure (Heart Failure) - Pipeline by CCRP Therapeutics GmbH, H1 2019
Congestive Heart Failure (Heart Failure) - Pipeline by Celixir Ltd, H1 2019
Congestive Heart Failure (Heart Failure) - Pipeline by Daiichi Sankyo Co Ltd, H1 2019
Congestive Heart Failure (Heart Failure) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2019
Congestive Heart Failure (Heart Failure) - Pipeline by Hemostemix Inc, H1 2019
Congestive Heart Failure (Heart Failure) - Pipeline by Immunwork Inc, H1 2019
Congestive Heart Failure (Heart Failure) - Pipeline by Innopharmax Inc, H1 2019

LIST OF FIGURES

Number of Products under Development for Congestive Heart Failure (Heart Failure), H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Number of Products by Top 10 Targets, H1 2019
Number of Products by Stage and Top 10 Targets, H1 2019
Number of Products by Top 10 Mechanism of Actions, H1 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
Number of Products by Top 10 Routes of Administration, H1 2019
Number of Products by Stage and Top 10 Routes of Administration, H1 2019
Number of Products by Top 10 Molecule Types, H1 2019
Number of Products by Stage and Top 10 Molecule Types, H1 2019

COMPANIES MENTIONED

Actelion Pharmaceuticals Ltd
Adrenomed AG
Amgen Inc
Araim Pharmaceuticals Inc
ARCA biopharma Inc
Arena Pharmaceuticals Inc
Ascendia Pharmaceuticals LLC
Astellas Pharma Inc
AstraZeneca Plc
Athersys Inc
Bayer AG
BEAT BioTherapeutics Corp
Betagenon AB
BioCardia Inc
BlueRock Therapeutics
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Co
C&C BioPharma LLC
Capricor Therapeutics Inc
Cardiol Therapeutics Inc
CCRP Therapeutics GmbH
Celixir Ltd
Daiichi Sankyo Co Ltd
F. Hoffmann-La Roche Ltd
Hemostemix Inc
Immunwork Inc
Innopharmax Inc
Inserm Transfert SA
Intra-Cellular Therapies Inc
Japan Tobacco Inc
Juventas Therapeutics Inc
KBP BioSciences Co Ltd
La Jolla Pharmaceutical Company
Lead Discovery Center GmbH
Les Laboratoires Servier SAS
Lexicon Pharmaceuticals Inc
Merck & Co Inc
Mesoblast Ltd
Miragen Therapeutics Inc
Mitsubishi Tanabe Pharma Corp
Moderna Therapeutics Inc
MyoKardia Inc
NanoCor Therapeutics Inc
Novartis AG
Otsuka Holdings Co Ltd
Oxstem Ltd
Palatin Technologies Inc
Paradigm Biopharmaceuticals Ltd
Pfizer Inc
PharmaIN Corp
PhaseBio Pharmaceuticals Inc
Q BioMed Inc
Quantum Genomics SA
Recardio GmbH
Renova Therapeutics Inc
resTORbio Inc
Ribomic Inc
Saje Pharma LLC
Sarfez Pharmaceuticals Inc
Senju Pharmaceutical Co Ltd
Shenzhen Salubris Pharmaceuticals Co Ltd
Shin Poong PharmCo Ltd
Sorrento Therapeutics Inc
Stemedica Cell Technologies Inc
Sun Pharma Advanced Research Company Ltd
Takeda Pharmaceutical Co Ltd
Theravance Biopharma Inc
Toa Eiyo Ltd
Torrent Pharmaceuticals Ltd
U.S. Stem Cell Inc
Vifor Pharma Ltd
Windtree Therapeutics Inc
XyloCor Therapeutics Inc
Zensun (Shanghai) Sci & Tech Co Ltd
Skip to top


Ask Your Question

Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2019
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: